Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E. Lipinski, Edina Komlódi-Pásztor, Özlem Göker-Alpan · Clinical Investigation · 2014
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Clinical Investigation · OMICS Publishing Group · article · 2014
Abstract
Enzyme replacement therapies substitute particular enzymes in individuals who have deficient or absent levels of enzymatic activity due to inherited defects. Fabry disease, a rare X-linked genetic disorder yet common lysosomal storage disease, is due to the impaired activity of α-galactosidase A. Currently, there are two enzyme preparations available for the treatment of Fabry disease: agalsidase alfa (Replagal®), manufactured by Shire, and agalsidase beta (Fabrazyme®), manufactured by Genzyme. Here, we review the molecular characteristics and intracellular trafficking of the endogenous and exogenous enzymes as well as the pharmacological properties of Replagal.
We also summarize clinical experiences with Replagal and provide insight into its therapeutic value for the treatment of Fabry disease.
Open the resolved locator · 10.4155/cli.14.35
Metadata licence: OpenAlex metadata (CC0)